Sutro Biopharma Inc. has formed a strategic partnership with the FDA to develop reference materials for antibody drug conjugates, aiming to enhance regulatory standards and accelerate the availability of innovative cancer treatments.

Sutro Biopharma, a biotech company, is engaging with investors through upcoming conferences to boost confidence and reassure stakeholders of its potential for long-term success.